Gilead Sciences

Open: 73.96 Close: 75.12 Change: 1.16

You'll be sorry if you don't use an AI to decide whether to invest in Gilead Sciences Company Inc.

The game is changing. There is a new strategy to evaluate Gilead Sciences fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, stock, news, medicine, year, company, …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences has one of the strongest and most diverse pipelines of new medicines in its history. The expansion of Gileads into cancer medicines represents a strategic diversification.

Today's News

Gilead Sciences, Inc. (gild) stock news | stock titan. gilead sciences, inc. (Gild) (gilad sciences) ( gild) Stock news page includes high-quality news articles accompanied by expert summary from Rhea-AI. Gilead Sciences, Inc. (GILD) announced its buying the developer of medicine for liver and other chronic diseases for $4.3 billion. Shares of Kyverna Therapeutics (CBAY) soared to an all-time high Monday. Gilead Sciences has one of the strongest and most diverse pipelines of new medicines in its history. The expansion of Gileads into cancer medicines represents a strategic diversification. Gilead Sciences has on average historically risen by 22.5% based on the past 32 years of stock performance. Over the next 52 weeks, the company has risen higher in 19 of those 32. Gilead Sciences stock price is 75.12 USD today. Gileads is a publicly traded company. Analysts estimate an earnings increase this quarter of $0.02 per share, a decrease next quarter of$0.14. Gilead Sciences shareholders are down 7.4% for the year (even including dividends), but the market itself is up 26%. Shareholders have been pleased with their favorable 38% return over the last five years. Gilead Sciences (GILD) closed at $73.66, indicating a +1.42% shift from the previous trading day. The company has a Zacks Rank of #Hold of $3.3.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Gilead, Sciences, stock, news, medicine, year, company, and the most common words in the summary are: gilead, science, job, stock, hiv, company, news, . One of the sentences in the summary was: The expansion of Gileads into cancer medicines represents a strategic diversification.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #job #stock #hiv #company #news.